300759:SZSEPharmaron Beijing Co., Ltd. Class A Analysis

The stock is trading at CNY 22.71, well under its 20‑day (23.54), 50‑day (26.85) and 200‑day (29.52) simple moving averages, indicating a short‑term bearish bias. Nonetheless, the MACD line has crossed above its signal line, generating a bullish histogram (+0.08) and suggesting a possible momentum reversal. RSI sits at 35.8, edging toward oversold territory, which could support a bounce. Volume has been rising, with today’s turnover exceeding the 10‑day average, adding weight to the reversal signal. The 30‑day volatility is elevated at 28.4%, reflecting a noisy price environment. Support is anchored at CNY 21.01, while resistance sits near CNY 26.80, framing the next price corridor.
On the fundamentals side, revenue grew 15.5% year‑over‑year to CNY 14.6 bn, and margins remain respectable (gross 34%, operating 13%). The trailing P/E of 23.9 is essentially in line with the industry average of 24.1, yet the forward P/E drops to 16.5, implying earnings acceleration. A discounted cash‑flow model values the company at CNY 26.1, delivering roughly 60% upside from the current level. The dividend yield of 0.9% is backed by a modest 21% payout ratio and a solid cash position, making the payout sustainable. Debt‑to‑equity stands at 41%, and while free cash flow is negative, operating cash flow remains positive, indicating cash generation capacity. Combined with a low beta of 0.55 and a diversified global client base, the stock offers a blend of growth potential and relative stability.